Ann: 2018 AGM Presentation, page-24

Hi pivalde, my take here is that this is just another fluctuation. They slowly walk the price down with no news, then drive it back up with or without news. Progress is painfully slow in this neurodegeneration drug space. Note nobody has developed an effective AD drug, and that includes pharma's with multi billion dollar R&D budgets. PSP drug development sent one small company I was following broke. Nobody has developed an effective ALS treatment. Animal models have not been very successful. The last successful HD drug development, led by Dr Stamler's team for Auspex (now Prana's Dr Stamler) was an adaptation of the previous approved HD drug. Prana's Ira Shoulson was instrumental in the approval of both drugs tetrabenazine and dutetetrabenazine. These guys are now in Prana's US based development team for PBT434. I fail to see how there could be no hope here. Auspex was acquired by the giant Teva for $3.2 billion in enterprise value and approximately $3.5 billion in equity value in 2015. 

I think Prana could be more forthcoming on info from the screening of new compounds using the new 3D human neuron model they now have. I guess there will be news as patents are registered?

Note, as far as I can see Auspex had no approved drugs at the time of the acquisition and was founded in 2001. Dutetetrabenazine had completed phase3.

All just my opinion. DYOR